Tessier-Lavigne Marc
- SEC CIK
- 0001437435
No open-market purchases or sales filed in the past year.
Current role at each company
- DNLI Denali Therapeutics Inc.Directoras of Jun 5, 2025
- REGN Regeneron Pharmaceuticals, Inc.Directoras of Jan 5, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Tessier-Lavigne Marc as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
DNLI Denali Therapeutics Inc.
Director7 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2021 (view filing) | Dec 28-30 | 2 days | Tessier-Lavigne MarcDirector | SSale | −63.1K | $44.43 | −$2.81M | −44.5%78.8K after | 12 lots |
| Jun 28, 2022 (view filing) | Mar 23 | 97 days | Tessier-Lavigne MarcDirector | SSale | −20.0K | $33.83 | −$676.6K | −1.0%2.02M after | Amended2 lots |
| Jul 27, 2022 (view filing) | Jul 25 | 2 days | Tessier-Lavigne MarcDirector | SSale | −20.0K | $35.61 | −$712.1K | −1.0%1.95M after | 2 lots |
| Aug 25, 2022 (view filing) | Aug 23 | 2 days | Tessier-Lavigne MarcDirector | SSale | −20.0K | $31.61 | −$632.3K | −1.0%1.93M after | 2 lots |
| Sep 30, 2022 (view filing) | Sep 28 | 2 days | Tessier-Lavigne MarcDirector | SSale | −20.0K | $30.82 | −$616.3K | −1.0%1.91M after | 2 lots |
| Nov 3, 2022 (view filing) | Nov 1-2 | 2 days | Tessier-Lavigne MarcDirector | SSale | −20.0K | $30.27 | −$605.5K | −1.0%1.89M after | 2 lots |
| Nov 28, 2022 (view filing) | Nov 23 | 5 days | Tessier-Lavigne MarcDirector | SSale | −20.0K | $30.48 | −$609.6K | −1.1%1.87M after |
REGN Regeneron Pharmaceuticals, Inc.
Director5 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2021 (view filing) | Sep 13 | 2 days | Tessier-Lavigne MarcDirector | SSale | −12.8K | $641.71 | −$8.18M | −86.0%2.08K after | 17 lots |
| Dec 10, 2021 (view filing) | Dec 9 | 1 day | Tessier-Lavigne MarcDirector | SSale | −3.78K | $665.00 | −$2.52M | −64.6%2.08K after | |
| Mar 18, 2022 (view filing) | Mar 16-17 | 2 days | Tessier-Lavigne MarcDirector | SSale | −12.2K | $678.21 | −$8.27M | −84.3%2.27K after | 2 lots |
| Mar 23, 2022 (view filing) | Mar 21 | 2 days | Tessier-Lavigne MarcDirector | SSale | −7.44K | $690.00 | −$5.13M | −76.6%2.27K after | |
| Oct 3, 2022 (view filing) | Sep 29-Oct 3 | 4 days | Tessier-Lavigne MarcDirector | SSale | −10.8K | $702.24 | −$7.61M | −82.7%2.27K after | 14 lots |